Date: 2017-06-05
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at ASM Microbe 2017
Company: Melinta Therapeutics (USA - CT)
Product: RX-P2177
Action
mechanism: antibiotic. RX-P873 is a novel pyrrolocytosine antibiotic that inhibits protein synthesis at the translation step.
Disease: gonorrhea
Therapeutic
area: Infectious diseases
Country:
Trial
details:
Latest
news:
- • On June 5, 2017, Melinta Therapeutics announced that an oral presentation on the potential of RX-P2177 in the treatment of gonorrhea was made at ASM Microbe 2017. Dr. Andrea Marra, Melinta Therapeutics’ director of biology and pharmacology, discussed the bactericidal and intracellular killing activity of RX-P2177 against strains of Neisseria gonorrhoeae during a symposium on antimicrobial pharmacokinetics and pharmacodynamics.
- RX-P2177 was shown to have strong activity in vitro against contemporary clinical gonorrhea isolates, including those resistant to ceftriaxone, ciprofloxacin and azithromycin. Its bactericidal activity extended to intracellular killing in both urethral and cervical epithelial cells, which are common sites of gonorrhea infection. Importantly, RX-P2177 was able to reduce gonorrhea burden by 1,000-fold (3-log10) in four hours against a CDC-approved reference strain, ATCC49226, as well as other clinical isolates.
Is
general: Yes
